Blood Glucose Hold Parameter for Fiasp
For adults using Fiasp (insulin aspart), hold the dose if blood glucose is less than 70 mg/dL (3.9 mmol/L) prior to administration, as this represents the threshold for clinically significant hypoglycemia that requires intervention.
Rationale and Evidence-Based Approach
The hold parameter for Fiasp should align with established hypoglycemia thresholds rather than hyperglycemia treatment targets. While the provided guidelines focus on when to initiate insulin therapy (≥180 mg/dL for hospitalized patients 1) and treatment targets (100-180 mg/dL range 1), the critical safety consideration is preventing insulin administration when glucose is already low.
Key Safety Thresholds
The standard hypoglycemia definitions guide hold parameters:
- Level 1 Hypoglycemia: <70 mg/dL (<3.9 mmol/L) - This is your primary hold threshold
- Level 2 Hypoglycemia: <54 mg/dL (<3.0 mmol/L) - Clinically significant hypoglycemia requiring immediate treatment
- Level 3 Hypoglycemia: Severe cognitive impairment requiring assistance
Clinical Context Matters
In hospitalized non-critical care settings:
- Hold Fiasp if pre-meal glucose <70 mg/dL
- Target range is 100-180 mg/dL 1
- For persistent hyperglycemia (≥2 readings ≥180 mg/dL in 24 hours), scheduled insulin should be added 1
In critical care settings:
- Hold if glucose <70 mg/dL
- Initiate insulin protocols for persistent hyperglycemia ≥180 mg/dL 2
- Target range 140-200 mg/dL (7.8-11.1 mmol/L) in critically ill adults 2
Fiasp-Specific Considerations
Fiasp is an ultra-rapid acting insulin with faster onset than standard insulin aspart. Research demonstrates it provides effective postprandial control 3 with similar hypoglycemia rates to standard insulin aspart 4, 5, 6, 7. The FDA label confirms hypoglycemia is the most common adverse reaction 8.
Important timing consideration: Fiasp acts within 2.5 minutes and peaks faster than regular insulin aspart, so the pre-dose glucose check must be performed immediately before administration (within 0-2 minutes of eating 8).
Common Pitfalls to Avoid
- Don't use hyperglycemia thresholds as hold parameters - The 180 mg/dL threshold is for initiating insulin therapy, not for holding doses
- Don't delay the pre-dose glucose check - With Fiasp's ultra-rapid action, glucose must be checked immediately before dosing
- Don't ignore trending glucose values - If glucose is 75 mg/dL but trending down rapidly, use clinical judgment to hold or reduce the dose
- Don't forget to reassess - If dose is held for low glucose, recheck glucose after treating hypoglycemia and before next scheduled dose
Additional Safety Parameters
Consider holding or reducing Fiasp dose if:
- Patient is NPO (nothing by mouth) unexpectedly
- Patient unable to eat full meal
- Recent episode of severe hypoglycemia
- Significant reduction in carbohydrate intake
- Acute kidney injury (insulin clearance affected)